20:32 , Oct 12, 2017 |  BC Extra  |  Company News

Lilly's Verzenio gets Priority Review for label expansion

Eli Lilly and Co. (NYSE:LLY) said FDA accepted and granted Priority Review to an NDA for Verzenio abemaciclib as a first-line endocrine therapy in combination with an aromatase inhibitor to treat hormone receptor-positive, HER2-negative advanced...
20:17 , Sep 22, 2017 |  BC Week In Review  |  Clinical News

Lilly reports additional Phase III breast cancer data for abemaciclib

Eli Lilly and Co. (NYSE:LLY) reported additional data from the Phase III MONARCH 3 trial in 493 postmenopausal women with hormone receptor-positive, HER2-negative, locoregionally recurrent or metastatic breast cancer showing that median progression-free survival, the...
03:09 , Jun 9, 2017 |  BC Week In Review  |  Clinical News

Lilly reports detailed MONARCH 2 data of abemaciclib in breast cancer

Eli Lilly and Co. (NYSE:LLY) reported additional data from Phase III MONARCH 2 trial in 669 postmenopausal women with hormone receptor-positive, HER2-negative breast cancer showing that twice-daily 150 mg oral abemaciclib (LY2835219) plus Faslodex fulvestrant...
21:05 , Apr 27, 2017 |  BC Week In Review  |  Clinical News

Abemaciclib: Interim Ph III MONARCH 3 data

Interim data from the double-blind, placebo-controlled, international Phase III MONARCH 3 trial in 493 postmenopausal women with hormone receptor-positive, HER2-negative, locoregionally recurrent or metastatic breast cancer showed that twice-daily 150 mg oral abemaciclib plus anastrozole...
20:30 , Apr 24, 2017 |  BC Extra  |  Clinical News

Lilly's abemaciclib passes latest MONARCH test

Eli Lilly and Co. (NYSE:LLY) said abemaciclib (LY2835219) significantly improved progression-free survival (PFS) in the Phase III MONARCH 3 trial to treat hormone receptor-positive, HER2-negative advanced breast cancer, meeting the study's primary endpoint. The company...
20:51 , Mar 23, 2017 |  BC Week In Review  |  Clinical News

Abemaciclib: Additional Ph III MONARCH 2 data

Additional data from the double-blind, placebo-controlled, international Phase III MONARCH 2 trial in 669 postmenopausal women with hormone receptor-positive, HER2-negative breast cancer showed that twice-daily 150 mg oral abemaciclib plus Faslodex fulvestrant met the primary...
04:31 , Jan 27, 2017 |  BC Week In Review  |  Clinical News

Abemaciclib: Final Ph II neoMONARCH data

Final data from the open-label, international Phase II neoMONARCH trial in 224 postmenopausal women with previously untreated, early stage hormone receptor-positive, HER2-negative breast cancer showed that twice-daily 150 mg oral abemaciclib alone and in combination...
07:00 , Oct 17, 2016 |  BC Week In Review  |  Clinical News

Faslodex fulvestrant: Additional Phase III data

Additional data from the double-blind, double-dummy, international Phase III FALCON trial in 462 postmenopausal women with hormone receptor-positive, locally advanced or metastatic breast cancer who have not previously received any hormonal treatment showed that first-line...
07:00 , Jul 11, 2016 |  BC Week In Review  |  Clinical News

Faslodex fulvestrant: Phase III data

The double-blind, double-dummy, international Phase III FALCON trial in about 524 postmenopausal women with hormone receptor-positive locally advanced or metastatic breast cancer who have not previously received any hormonal treatment showed that first-line treatment with...
08:00 , Dec 22, 2014 |  BC Week In Review  |  Clinical News

Faslodex fulvestrant: Phase II data

The open-label, international Phase II FIRST trial in 205 patients with hormone receptor-positive locally advanced or metastatic breast cancer showed that first-line treatment with 500 mg intramuscular Faslodex on days 0, 14 and 28 followed...